Eric Yuen

Eric Yuen is a clinical development physician with over 20 years of experience in academia and industry. During his career, Dr. Yuen has developed numerous biologics and small molecule therapeutics for a variety of diseases, including rare genetic diseases and neurology, psychiatry, pain, and oncology disorders. Dr. Yuen has led departments responsible for Phase I-IV development and submissions of numerous INDs, CTAs, NDAs, and MAAs. Eric was the Director of Clinical Research at Merck & Co., working on CNS and pain indications, and later Vice President of Clinical Development at Johnson & Johnson, where he served as the therapeutic area head for CNS and the head of clinical development at a monoclonal antibodies and vaccines joint venture between Johnson & Johnson and Elan. Eric later served as Chief Medical Officer for Ultragenyx, a start-up company focused on rare genetic diseases, and as VP Clinical Development at BioClin Therapeutics, a start-up focused on the rare genetic disorder achondroplasia (dwarfism) and bladder cancer. Eric serves as the Chief Medical Officer of Spirovant Sciences. Earlier in his career, Dr. Yuen was an assistant professor of neurology at the University of Washington. Eric completed his undergraduate education at Stanford University, received his MD from the Pritzker School of Medicine at the University of Chicago, completed his neurology residency at UCSF, and was a post-doctoral fellow in the laboratory studying neurotrophic factor signaling at UCSF.